Common Cold
| Use attributes for filter ! | |
| Google books | books.google.com |
|---|---|
| Originally published | 2009 |
| Authors | Ronald Eccles |
| Editors | Ronald Eccles |
| Olaf Weber | |
| Date of Reg. | |
| Date of Upd. | |
| ID | 2961959 |
About Common Cold
The common cold is unlike any other human disease because of two f- tors: firstly, it is arguably the most common human disease and, secondly, it is one of the most complex diseases because of the number of viruses that cause the familiar syndrome of sneezing, sore throat, runny nose and nasal congestion. . . .
US approves postpartum depression pill
... It noted that the most common side-effects from taking Zurzuvae can include drowsiness, dizziness, diarrhoea, fatigue, the Common Cold, and urinary tract infection...
Eurovision 2023: Every song ranked, from Albania to the UK
... I Wrote A Song is a frank and funny revenge track, bitter as a bag of lemons and catchier than the Common Cold...
Have I dodged Covid and what does it mean?
... They are probably the result of catching other Common Cold coronaviruses, which are closely related to the Covid virus...
North Korea: Fighting Covid with traditional medicine
... Some studies suggest gargling and nasal rinses with salt water combat viruses that cause the Common Cold...
Covid: Can I catch Omicron twice?
... Most people can expect to catch the other coronaviruses, such as those which cause Common Cold symptoms, many times in their life...
Covid trapped me at home for more than seven months
... Even a Common Cold can linger...
Covid immunity: Can you catch it twice?
... Four produce the symptoms of the Common Cold and immunity is short-lived...
Unvaccinated man denied heart transplant by Boston hospital
... Dr Arthur Caplan, head of medical ethics at NYU Grossman School of Medicine, told CBS News that after any organ transplant a patient s immune system is all but shut down and even a Common Cold can prove fatal...
US approves postpartum depression pill
By Aoife WalshBBC News
The US has approved The First pill for postpartum depression.
The Food and Drug Administration (FDA) said zuranolone, sold under the brand name Zurzuvae, has been approved as a once-daily pill taken for Two Weeks .
Until Now , treatment for postpartum depression (PPD) was available only as an intravenous injection, the FDA said.
Drug manufacturers Sage Therapeutics and Biogen said the pill is expected to be available later this year. No price has yet been announced.
Similar to other forms of depression, symptoms of postpartum depression (PPD) can include sadness, loss of energy, suicidal thoughts, decreased ability to feel pleasure, or cognitive impairment, according to the FDA.
It is estimated that one in seven women experience symptoms of PPD in the US,
" Postpartum depression is a serious and potentially life-threatening condition in which women experience sadness, guilt, worthlessness—even, in severe cases, thoughts of harming themselves or their child, " said Tiffany Farchione, head of psychiatry in the FDA's Center for Drug Evaluation and Research.
" And, because postpartum depression can disrupt the maternal-infant bond, it can also have consequences for The Child 's physical and emotional development. "
Access to an oral medication will be beneficial for many women " coping with extreme, and sometimes life-threatening, feelings" she added.
Clinical trials showed the pill helped to significantly reduce depressive symptoms within Three Days . The effect of the medication was maintained at four weeks after The Last dose, the FDA said.
It noted that The Most common side-effects from taking Zurzuvae can include drowsiness, dizziness, diarrhoea, fatigue, the Common Cold , and urinary tract infection.
The Agency said labelling contains a boxed warning noting that Zurzuvae can affect a person's ability to drive and perform other potentially hazardous activities. It recommends patients should not drive or operate Heavy Machinery for at least 12 Hours after taking it.
Sage Therapeutics and Biogen had also sought approval to use zuranolone for major depressive disorder (MDD), or clinical depression. However, the FDA said the medication did not provide substantial evidence of effectiveness and said an additional study or studies would be needed.
The companies said they were evaluating their next steps.
Sage Therapeutic said it was " highly disappointed for patients, particularly amid the current Mental Health crisis and millions of people with MDD struggling to find symptom relief. "
Related TopicsSource of news: bbc.com